Ketamine Troches for Depression: Evidence and Protocols

Ketamine troches for depression are sublingual lozenges that deliver ketamine's rapid antidepressant effect without an IV line, and a growing body of clinical evidence supports their use for treatment-resistant depression (TRD) when doses are properly titrated. Traditional antidepressants, including SSRIs, SNRIs, TCAs, and MAOIs, all target the same serotonin, norepinephrine, and dopamine systems. According to the National Institute of Mental Health, a substantial share of people with major depressive disorder do not reach remission even after multiple adequate antidepressant trials, a pattern clinicians call treatment-resistant depression. The World Health Organization estimates that depression affects more than 280 million people worldwide, making it one of the leading causes of disability globally, according to the WHO Depression Fact Sheet. Ketamine works through a mechanistically distinct pathway, which is why it has produced rapid, robust antidepressant effects in many TRD patients who had already failed several prior treatments. This article reviews the clinical evidence, the biology behind the effect, and what a typical ketamine troche protocol for depression looks like.

Ketamine's antidepressant effect starts with blockade of the NMDA (N-methyl-D-aspartate) receptor, a glutamate-gated ion channel involved in synaptic plasticity. The StatPearls clinical reference on ketamine describes how this initial blockade sets off a chain of downstream effects rather than acting through direct mood elevation:

• NMDA blockade on inhibitory interneurons releases excitatory glutamate signaling at AMPA receptors.
• AMPA activation triggers rapid release of brain-derived neurotrophic factor (BDNF), a protein that supports synaptic growth.
• BDNF activates the mTOR signaling pathway, which drives synthesis of proteins needed to build new synapses.
• New synaptic connections form in prefrontal and limbic brain regions involved in mood regulation, areas that show measurable synaptic loss in chronic depression.

This process, sometimes called the synaptic restoration hypothesis of depression, is supported by both animal studies and human neuroimaging research. Ketamine's metabolite (2R,6R)-hydroxynorketamine (HNK) appears to contribute as well; unlike ketamine itself, HNK does not block NMDA receptors but modulates AMPA signaling through a separate pathway, which may explain antidepressant activity even at doses too low to fully block NMDA receptors. Chemical structure and metabolism data are available through the PubChem ketamine compound summary. Depression also has a documented inflammatory component in a subset of patients, with elevated inflammatory markers such as IL-6, TNF-alpha, and CRP. Ketamine has shown anti-inflammatory activity in multiple studies, which may add a second mechanism of benefit for patients whose depression has this inflammatory signature.

Direct evidence for sublingual ketamine troches is smaller than the IV literature but consistent with it. A 2017 review by Andrade examined case series and observational data supporting sublingual ketamine for treatment-resistant depression, and real-world outcome data from outpatient telehealth practices using troches has reported response rates broadly in line with IV results when doses are properly titrated. The home-based troche format introduces more variability in absorption than a clinic-administered IV infusion, which is why dose titration and technique matter more with this route. Our guide to sublingual versus buccal placement covers how administration technique affects absorption, and the onset, peak, and duration timeline explains what to expect session to session. The sublingual evidence base is thinner than the IV literature, but the underlying mechanism is identical, and clinical experience with troches in appropriately selected patients has been favorable.

Response to ketamine troche therapy is rarely instantaneous after one session. Most patients notice improved sleep, less emotional numbness, and brief windows of lighter mood within the first few sessions. By the second to fourth session, mood improvement tends to become more sustained, with less rumination and hopelessness. By the end of a full acute course, many patients see a meaningful reduction in depressive symptoms, often 50 percent or more on standard clinical scales, along with improved function and increased engagement in daily activities. The effect builds across the acute course rather than resetting after each session, which is part of why consistent dosing matters more than any single treatment.

Ketamine is not a standalone cure for depression. It opens a neurobiological window of plasticity, a period during which the brain is more capable of change, but what happens during and after that window determines whether the change lasts. Patients who pair troche therapy with regular integration psychotherapy, lifestyle changes such as exercise, sleep hygiene, and social connection, and active work on cognitive and behavioral patterns tend to show more durable responses than those who use ketamine in isolation. Working closely with a prescribing provider throughout treatment also matters for dose adjustment and safety monitoring over the course of therapy.